Evidence map›Paper›PMID 42291352›Full record

ArticleTranslational lung cancer research2026

Duration of systemic therapy in patients with metastatic

Michael Yan, Michael Tjong, Natalie Coburn, Lena Nguyen, Arjun Sahgal, Alexander V Louie, Ambica Parmar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael YanRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-8387-6563
Michael TjongDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Natalie CoburnOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Lena NguyenInstitute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada.
Arjun SahgalDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Alexander V LouieDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Ambica ParmarOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib, a third-generation epidermal growth factor receptor ( Methods: We performed an observational study using provincial administrative databases. All patients with Results: Among 3,541 eligible patients, 481 met inclusion criteria (osimertinib: 222; gefitinib: 259). Median first-line treatment duration was significantly longer with osimertinib than with gefitinib (12.6 Conclusions: In real-world practice, osimertinib is associated with longer first-line treatment duration, improved CNS control, and longer survival compared with gefitinib among

Indexed as

brain metastasesEGFR mutationNon-small cell lung cancer (NSCLC)osimertinibtyrosine kinase inhibitors (TKIs)

Identifiers

PMID42291352
PMCPMC13263819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.